1. Scrip
  2. >>Business

Severe and Asymptomatic Data Could Give Moderna’s COVID-19 Vaccine Slight Edge Over Pfizer’s

 
• By Sarah Karlin-Smith

Moderna’s COVID-19 vaccine looks better than Pfizer/BioNTech’s at preventing severe disease and like it may offer some benefit in preventing asymptomatic infections, but these advantages may be short-lived and hard to capitalize on due to supply limitations.    

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
• Source: Shutterstock

Moderna, Inc.’s COVID-19 vaccine will head into its 17 December US Food and Drug Administration advisory committee review with more solid data on its impact on severe disease than competitor Pfizer Inc./BioNTech SE’s had when that vaccine went in front of the same committee last week. Moderna also has some preliminary data on its vaccine’s ability to prevent transmission of the virus, of which Pfizer had none.

With an overall similar efficacy and safety profile to Pfizer’s product, Moderna is all but guaranteed to receive the second...

More from Business

More from Scrip

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 
• By Jessica Merrill

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.